Remove COVID-19 Vaccine Remove Licensing Remove Public Health
article thumbnail

COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues

Bill of Health

Moderna also licensed their mRNA technology from Cellscript LLC – University of Pennsylvania’s successor-in-interest to the 966 patent. Indeed, as made public, the U.S. government committed more than one billion dollars to Moderna for development of its COVID-19 vaccines.

article thumbnail

No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge

Bill of Health

Legally speaking, patent pledges are comparable to the open source software licenses that underlie much of the world’s technology infrastructure and the Creative Commons licenses that make billions of online images, videos and other content freely available (both discussed here ). Tesla and Toyota) to software (e.g,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?

Bill of Health

The National Institutes of Health (NIH) is currently embroiled in a dispute over the ownership of patent rights to Moderna’s flagship mRNA COVID-19 vaccine (mRNA-1273). Failing to do so would be a missed opportunity for the public sector to have a say in the distribution and pricing of this critical medical technology.

article thumbnail

COVID ‘Compromise’ on International IP Underscores Need for New Approach

Bill of Health

It only narrowly modifies compulsory licenses of patents covering COVID vaccines. Moreover, it imposes additional restrictions on use of compulsory licenses. Moreover, Brazil’s new compulsory license law models another critical feature that domestic laws should have – a way around data exclusivity. Third, the U.S.

COVID-19 313
article thumbnail

Unlocking the mRNA Platform Technology: Walking the Talk with Investment Protection

Bill of Health

By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. government substantially de-risking the vaccine development process.

article thumbnail

Using Contracts to Lessen Inequities in Access to Medicines in Pandemics and Epidemics

Bill of Health

Research funding contracts can help to safeguard against profound inequities in global allocation and distribution of lifesaving diagnostics, drugs, and vaccines. During large transnational public health crises, global demand soars for diagnostics, drugs, and vaccines. Using Contracts to Further Equity Goals.

article thumbnail

Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’

Bill of Health

Some COVID-19 vaccine manufacturers in the US have refused to share vaccine samples for research purposes , creating an access issue with the potential to delay comparator studies, follow-on research, and new vaccine / drug development. By Aparajita Lath.

COVID-19 173